Godlike Productions - Discussion Forum
Users Online Now: 2,133 (Who's On?)Visitors Today: 961,128
Pageviews Today: 1,714,932Threads Today: 733Posts Today: 13,018
07:25 PM


Rate this Thread

Absolute BS Crap Reasonable Nice Amazing
 

FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart

 
Anonymous Coward
User ID: 76983471
United States
04/24/2020 10:41 AM
Report Abusive Post
Report Copyright Violation
FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart
American Association of Poison Control Centers National Poison Data System concerning serious heart-related adverse events and death in patients with COVID-19 receiving hydroxychloroquine and chloroquine, either alone or combined with the antibiotic azithromycin or other medicines. These adverse events included abnormal heart rhythms such as QT interval prolongation, dangerously rapid heart rate called ventricular tachycardia and ventricular fibrillation, and in some cases, death. Patients who also have other health issues such as heart and kidney disease are likely to be at increased risk of these heart problems when receiving these medicines.


More: [link to www.fda.gov (secure)]
ROOSTRE

User ID: 78190861
United States
04/24/2020 10:58 AM
Report Abusive Post
Report Copyright Violation
Re: FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart
American Association of Poison Control Centers National Poison Data System concerning serious heart-related adverse events and death in patients with COVID-19 receiving hydroxychloroquine and chloroquine, either alone or combined with the antibiotic azithromycin or other medicines. These adverse events included abnormal heart rhythms such as QT interval prolongation, dangerously rapid heart rate called ventricular tachycardia and ventricular fibrillation, and in some cases, death. Patients who also have other health issues such as heart and kidney disease are likely to be at increased risk of these heart problems when receiving these medicines.


More: [link to www.fda.gov (secure)]
 Quoting: Anonymous Coward 76983471


I was saying this since they first announced the use of HCQ. It can't be used in the very patients that need it the most.





GLP